Academic Journal
LBA2 Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up of the East Asian subgroup of the randomized phase III LITESPARK-005 trial
| العنوان: | LBA2 Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up of the East Asian subgroup of the randomized phase III LITESPARK-005 trial |
|---|---|
| المؤلفون: | Lee, J-L., Park, S.H., Kato, T., Saika, T., Masumori, N., Oya, M., Nishimoto, K., Fujimoto, H., Eto, M., Kishida, T., Lee, H.J., Su, Y-L., Miura, Y., Matsubara, N., Kitamura, H., Cheng, A.C.K., Xing, A., Perini, R., Vickery, D., Rini, B.I. |
| المصدر: | Annals of Oncology ; volume 35, page S1505 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2024 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2024.10.287 |
| الاتاحة: | https://doi.org/10.1016/j.annonc.2024.10.287 https://api.elsevier.com/content/article/PII:S0923753424043436?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0923753424043436?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; https://www.elsevier.com/legal/tdmrep-license |
| رقم الانضمام: | edsbas.A79C7369 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2024.10.287 |
|---|